Alafi Capital

Christopher Alafi, who holds a PhD in molecular and cell biology from UC Berkeley, and his father Moshe Alafi jointly manage the firm. Investment decisions rely on Christopher Alafi's scientific training combined with Moshe Alafi's five decades of venture experience in biotechnology. The firm has not publicly disclosed a broader investment committee structure.

Moshe Alafi was a founding figure in biotechnology venture capital, co-founding one of the sector's first dedicated funds and serving as an early backer of Amgen and Applied Biosystems. Alafi Capital represents an extension of that legacy, with Christopher Alafi carrying forward the family's specialization in science-driven, early-stage investing. This historical positioning gives the firm a deep network within academic research institutions and biotech ecosystems.

While biotechnology and life sciences form the historical core of the Alafi portfolio, the firm has also selectively backed enterprise software and AI/ML companies with biological or healthcare applications. The unifying thread is technical complexity and scientific defensibility, not a single industry category. The team's primary competence remains at the intersection of biology and engineering.

The firm's deal flow is heavily relationship-driven, leveraging generational ties to University of California campuses, particularly UC Berkeley and UCSF, as well as Stanford. Moshe Alafi's reputation as a biotech venture pioneer provides access to seasoned scientific founders, while Christopher Alafi's PhD background enables credible technical evaluation of early-stage research. This dual-pronged sourcing has sustained the firm without a large business development function.